2026-11-17 · MarketWatch · English source

The FDA declined to approve one of biotech’s most closely watched cancer drugs. The company’s stock tumbled.

Real-world example for IB, A-Level, AP and IGCSE Economics essays: Market power and competition policy, Information failure, Financial markets and banks

What happened

The FDA declined to approve Summit Therapeutics' closely watched lung-cancer drug, telling the company it must show the treatment helps patients live longer, and the company's stock fell sharply.

The economics

The case shows that regulatory approval is a key barrier shaping a pharmaceutical firm's market power: approval brings exclusive sales and pricing under patent protection, while rejection leaves potential market share unrealised. The demand for stronger efficacy evidence also reflects information asymmetry, since regulators require credible clinical data and investors reprice the firm based on approval signals.

Evaluation

The share-price fall reflects markets repricing approval risk in the short run, but long-run returns could recover if further trials succeed; strict approval protects patients yet may delay access to effective medicines.

Practice question

Using this example, discuss how government regulatory approval affects a pharmaceutical firm's market power and investment decisions.

Read the article ↗

Where it fits in the syllabus

  • Market power and competition policy: When a few firms control a market they can raise prices; governments use antitrust and regulation to protect competition.
  • Information failure: One side of a deal knows more than the other, so the market allocates resources badly.
  • Financial markets and banks: How banks, bond and stock markets fund the economy, and what swings in asset prices do.

中文版

发生了什么

美国食品药品监督管理局(FDA)拒绝批准Summit Therapeutics备受关注的肺癌药物,监管机构要求该药证明能延长患者生存期,公司股价随之大跌。

经济学角度

这一事件说明监管审批是制药企业市场力量的关键门槛:药物获批意味着专利保护下的独家销售和定价能力,被拒则使潜在市场份额无法实现。审批要求企业提供更充分的疗效证据,也体现了信息不对称——监管机构要求企业披露可信的临床数据,投资者则依据审批信号重新评估公司价值。

评估角度

短期股价下跌反映市场对审批风险的重新定价,但若企业后续补充试验并获批,长期收益可能恢复;同时严格审批保护患者安全,却也可能推迟有效药物上市。

练习题

结合该案例,讨论政府监管审批如何影响制药企业的市场力量与投资决策。

More cases on market power and competition policy

All cases in the Economics Case Library

Cases are written by AI from the article headline and lead, using only facts from the article; every quoted figure comes from it. Read the original before citing.